Atezolizumab is a humanised IgG1 anti-PD-L1 mAb that was originally approved for the treatment of urothelial carcinoma and later on also approved for NSCLC, melanoma, and hepatocellular carcinoma [28,29,30,31]. Here, CD274 is linked to urothelial carcinoma.